For decades, the search for a preventive HIV vaccine has faced setbacks. A virus that mutates rapidly and covers its vulnerable sites has long resisted traditional approaches. A new article published by Nature on August 1st explains how a phase 1 clinical trial publisjed last July in Science Transnational Medicine has offered a glimmer of hope: researchers report that an mRNA vaccine encoding membrane-anchored HIV envelope trimers has triggered neutralizing antibodies in humans at unprecedented levels.
The trial included 108 adults and tested three mRNA-based vaccine designs. After three doses, 80% of participants who received the membrane-anchored trimer developed tier 2 neutralizing antibodies, compared with only 4% in those given a soluble version. Neutralizing antibodies of this class are considered crucial for blocking HIV infection. The vaccines were generally well tolerated, although 6.5% of participants experienced urticaria (hives), a higher rate than observed with other mRNA vaccines, warranting close monitoring of safety signals.
This result marks the first demonstration in humans that mRNA vaccines can elicit tier 2 neutralization against HIV. It builds on earlier preclinical evidence that membrane-bound presentation of the viral envelope better mimics the virus itself and helps the immune system focus on the right targets.
At the same time, another complementary strategy has shown progress. A separate set of phase 1 trials in the United States, Rwanda, and South Africa tested mRNA delivery of engineered HIV nanoparticles designed to prime rare precursor B cells that can eventually develop into broadly neutralizing antibodies. The vaccines successfully activated these precursors in more than 90% of participants, confirming the feasibility of so-called germline-targeting approaches. Some participants developed lasting skin reactions, but the studies still showed that a step-by-step approach can guide the immune system to build broader antibody responses.
Taken together, these trials suggest that mRNA technology is transforming HIV vaccine science. The platform not only accelerates vaccine design and testing but also allows delivery of antigens in forms—such as membrane anchoring—that were difficult to achieve with proteins alone.
There is still a long way to go. The antibodies seen so far work mainly against specific strains, not broadly across HIV, so multi-step vaccination strategies will be needed to push the immune system further. Even so, progress is accelerating. As the trial authors noted, the findings point to “a promising platform for HIV vaccine clinical development.” If future studies confirm and extend these findings, mRNA-based HIV vaccines could finally shift the balance in a battle that has lasted more than forty years.
Coordinator at la Verneda-Sant Martí Learning Community and adjunct professor at the University of Barcelona